GlassScriptPhysician profile
Amy Mcclung
NPI 1033372586
$18,200.03
in general payments reported to CMS, 2019-2025
43 companies · $3,514 in 2025
The $3,514 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $1,367 · 2021: $1,909 · 2022: $2,704 · 2023: $3,264 · 2024: $3,865 · 2025: $3,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,315.21 |
| Education | $327.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,303.90 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $3,187.50 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,539.01 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,151.60 | 2019-2025 | |
| Lilly USA, LLC | $1,050.13 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $933.09 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $798.06 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $711.84 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Arcutis Biotherapeutics, INC. | $636.65 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $632.47 | 2021-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $607.23 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $530.13 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $513.61 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Dermavant Sciences, INC. | $374.18 | 2022-2024 | Vtama |
| Incyte Corporation | $339.49 | 2021-2025 | Opzelura |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $212.48 | 2020-2025 | Otezla, Otezla |
| Journey Medical Corporation | $180.94 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $179.81 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $164.62 | 2020-2021 | |
| Allergan, INC. | $148.48 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $115.47 | 2019-2024 | Cabtreo, Siliq, Targretin |
| Epi Health, LLC | $103.89 | 2020-2022 | |
| Kyowa Kirin, INC. | $92.86 | 2021-2023 | Poteligeo |
| Prugen, INC. Pharmaceuticals | $79.84 | 2019 | |
| Kerecis Limited | $77.86 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Aclaris Therapeutics, INC. | $60.48 | 2019 | |
| Botanix Sb INC | $50.37 | 2025 | Sofdra |
| Organon LLC | $49.30 | 2023-2025 | Vtama, Hadlima |
| Elekta, INC. | $39.01 | 2025 | Flexitron Hdr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.64 | 2022-2024 | Spevigo |
| Organogenesis INC. | $38.61 | 2025 | Apligraf |
| Strata Skin Sciences, INC. | $31.35 | 2024 | Xtrac |
| Nabriva Therapeutics, Plc | $28.07 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $26.99 | 2020-2022 | |
| Dermira, INC. | $25.59 | 2019-2020 | |
| Genentech USA, INC. | $24.93 | 2021-2022 | |
| Springworks Therapeutics, INC. | $24.07 | 2025 | Gomekli |
| Celgene Corporation | $23.43 | 2019 | |
| Smith+Nephew, INC. | $17.52 | 2025 | Collagenase Santyl |
| Lnhc, INC | $16.42 | 2025 | Zelsuvmi |
| Helsinn Therapeutics (U.S.), INC. | $15.86 | 2021 | |
| Revance Therapeutics, INC. | $13.08 | 2024 | Daxxify |
| Almirall LLC | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Mcclung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.